Drugs / FP-01.1
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT01265914 | Aug 2010 → Mar 2011 | influenza | Immune Targeting Systems Ltd | Completed | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT02071329 | Jan → Dec 2014 | influenza | Immune Targeting Systems Ltd | Completed | No outcome recorded |
| Comparator or background therapy2 trials | ||||||
| Phase 1 | NCT01701752 Comparator | Sep 2012 → Apr 2013 | influenza | Immune Targeting Systems Ltd | Completed | No outcome recorded |
| Phase 1 | NCT01677676 Comparator | Jan → May 2012 | influenza | Immune Targeting Systems Ltd | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 5 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | FP-01.1 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01677676 ↗ |
| Known as | Vaccine FP-01.1 | “prior vaccination with Vaccine FP-01.1 (250 μg/peptide) or placebo” NCT02071329 ↗ |
| Modality | Peptide | “FP-01.1 is a novel synthetic influenza A vaccine consisting of six fluorocarbon-modified 35-mer peptides” PMID 24928790 ↗ Jun 2014 |
| Route | Intramuscular | “Repeated Intramuscular Administration” NCT01265914 ↗ |